Scoop: Roche-backed startup gives up on CD47, lays off all employees
Arch Oncology ended its work on developing an anti-CD47 antibody and most employees have left the company, Endpoints News has learned.
The Brisbane, CA, and St. Louis biotech scrapped clinical development of the antibody, dubbed AO-176, according to an automatic reply email from a former clinical operations director.
All Arch employees were let go and the company “was in a wind-down situation,” according to the LinkedIn bio of Arch’s former VP of human resources.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.